InnoCyto Inc.
15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618

Technical Data Sheet

FITC Anti-human FcÎµRIÎ± Antibody

Catalog Number: 108109, 108110
Size: 25 tests, 100 tests
Target Name: Fc?RI?, High affinity IgE receptor, Fc?RI alpha, FceRIa, FceR1a
Regulatory Status: RUO

Product Details

Clone: AER-37
Application: Flow Cytometry
Reactivity: Human
Format: FITC
Isotype: Mouse IgG2b
Antibody Type: Monoclonal
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein Concentration: Supplied at a lot-specific concentration.
Storage&Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage: For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. FITC has an excitation max at 493 nm and an emission max at 525 nm.
Excitation Laser: Blue Laser (488 nm)
Release Date: Dec-25
Isotype Control: 301617

Background Information

FcεRIα (high-affinity immunoglobulin E receptor alpha subunit) is the primary binding component of the high-affinity receptor for IgE, known as FcεRI. This receptor plays a pivotal role in allergic responses and immune defense against parasites by mediating the activation of mast cells and basophils. Upon binding IgE, FcεRIα enables these cells to recognize antigens that cross-link surface-bound IgE, triggering potent inflammatory and allergic reactions through the release of histamine and other mediators.

Structurally, FcεRIα is a type I transmembrane glycoprotein of approximately 50-60 kDa, composed of an extracellular domain that binds the Fc portion of IgE with high specificity, a single transmembrane domain, and a short cytoplasmic tail. It is heavily glycosylated, and its extracellular region contains two immunoglobulin-like domains crucial for high-affinity IgE binding. FcεRIα pairs with the β and γ subunits, both of which contain immunoreceptor tyrosine-based activation motifs (ITAMs), to form the functional receptor complex on mast cells, basophils, and, at lower levels, on antigen-presenting cells such as dendritic cells and eosinophils. The α chain binds

InnoCyto Inc.
15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618

IgE, while the β and γ chains mediate signal transduction upon receptor aggregation. FcεRIα's ligand is the Fc region of IgE. When an allergen bridges IgE molecules bound to FcεRI, it initiates receptor aggregation and downstream signaling cascades involving tyrosine kinases such as Lyn and Syk, leading to the release of preformed granules and synthesis of cytokines, leukotrienes, and prostaglandins. This cascade underlies immediate hypersensitivity reactions, including asthma, allergic rhinitis, urticaria, and anaphylaxis.

In disease, overactivation or dysregulation of FcεRIα-mediated pathways drives allergic and atopic disorders. Elevated surface expression of FcεRIα on immune cells is commonly observed in allergic individuals, correlating with disease severity. Conversely, soluble forms of FcεRIα can modulate IgE availability, influencing immune reactivity.

Therapeutically, FcεRIα has become an important target for allergy treatment. Omalizumab, a monoclonal antibody that binds circulating IgE, prevents its interaction with FcεRIα, thereby reducing receptor expression and mast cell activation. Novel strategies aim to block IgE-FcεRIα interactions directly or modulate receptor signaling, offering potential for treating allergic disease, asthma, and related immune hypersensitivities.

Product Data



Human peripheral blood lymphocytes stained with PE Anti-human CD203c and either FITC Anti-Human FcERI? clone AER-37 (right panel) or an isotype control (left panel).